US FDA’s Makary Wants Lower Biosimilar Launch Prices As Clinical Study Mandate Changed

 
• By Derrick Gingery
  
FDA Commissioner Martin Makary, right, spoke about updated biosimilar guidance during a session at the AAM GRx-Biosims conference. (Derrick Gingery)

More from Biosimilars

More from United States